Which of the following is approved for brain perfusion imaging?

The correct choice for brain perfusion imaging is Exametazime. This radiopharmaceutical, often referred to by its brand name HMPAO (hexamethylpropyleneamine oxime), is specifically designed for quantifying cerebral blood flow and assessing brain perfusion. It is used in single photon emission computed tomography (SPECT) imaging, providing important diagnostic information in conditions such as stroke, seizures, and dementia by highlighting areas of the brain that are receiving adequate blood flow.

Exametazime is advantageous due to its ability to cross the blood-brain barrier and accumulate in brain tissue, resulting in a clear image that can be analyzed by healthcare professionals. The formulation allows for the radiotracer to be visualized effectively, making it a critical tool for neurologists and nuclear medicine specialists in diagnosing cerebral conditions.

Other options presented, such as Pentetreotide, Satumomab pendetide, and Teboroxime, are associated with different imaging purposes or conditions and are not indicated for brain perfusion imaging. For instance, Pentetreotide is primarily used in the detection of neuroendocrine tumors, while Satumomab pendetide is used in imaging of certain cancers. Teboroxime has mostly been employed in